Side-by-side comparison of AI visibility scores, market position, and capabilities
NYC YC W20 MSK Cancer Center spinout with FDA Breakthrough Device for whole-genome/transcriptome tumor profiling; $5M total (Two Sigma/NCI SBIR) competing with Foundation Medicine and Tempus AI for comprehensive genomic profiling in pediatric and rare cancers.
Isabl is a New York-based whole-genome and transcriptome cancer diagnostics company — backed by Y Combinator (W20) with $5 million in total funding including $3 million from Two Sigma Ventures, BoxOne Ventures, Bossa Invest, and Jude Gomilla, plus a $2 million SBIR grant from the National Cancer Institute (NCI) — commercializing the Isabl GxT (Genome x Transcriptome) diagnostic platform that received FDA Breakthrough Device Designation for comprehensive tumor profiling that analyzes entire tumor genomes and transcriptomes simultaneously to identify cancer-associated mutations, fusion genes, and expression patterns that guide treatment selection. Founded in 2020 after incubating at Memorial Sloan Kettering Cancer Center (MSKCC) from 2015-2019, Isabl's genomic testing platform is specifically advancing through March 2025 NCI funding for pediatric and rare solid cancers where comprehensive genomic profiling can identify targeted therapy opportunities that standard panel tests miss.
Global fast-fashion giant with 4,100+ stores across 78 markets. Q1 2026 revenue up 3%; investing in AI personalization and sustainability initiatives.
H&M Hennes & Mauritz is a Swedish multinational fashion retailer founded in 1947, operating brands including H&M, COS, & Other Stories, ARKET, and Weekday. The company runs approximately 4,100 stores worldwide with annual revenue of ~$23B, generating 66% of sales from Europe.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.